Cover Image

Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: a case report

Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TK...

Full description

Saved in:
Bibliographic Details
Main Authors: Longuespée, Rémi (Author) , Kunz, Julia (Author) , Fresnais, Margaux (Author) , Foerster, Kathrin (Author) , Burhenne, Jürgen (Author) , Thomas, Michael (Author) , Kazdal, Daniel (Author) , Stenzinger, Albrecht (Author) , Christopoulos, Petros (Author) , Haefeli, Walter E. (Author)
Format: Article (Journal)
Language:English
Published: January 2024
In: British journal of clinical pharmacology
Year: 2024, Volume: 90, Issue: 1, Pages: 344-349
ISSN:1365-2125
DOI:10.1111/bcp.15924
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/bcp.15924
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15924
Get full text
Author Notes:Rémi Longuespée, Julia Kunz, Margaux Fresnais, Kathrin I. Foerster, Jürgen Burhenne, Michael Thomas, Daniel Kazdal, Albrecht Stenzinger, Petros Christopoulos, Walter E. Haefeli
Description
Summary:Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
Item Description:Erstveröffentlichung: 10. Oktober 2023
Gesehen am 06.02.2024
Physical Description:Online Resource
ISSN:1365-2125
DOI:10.1111/bcp.15924

Similar Items